Standard BioTools Files S-4 for Reverse Merger with Treeline Biosciences, Revealing a $2.5B Valuation and 84% Treeline Ownership

summarizeSummary

Standard BioTools' S-4 reveals the full terms of its reverse merger with Treeline Biosciences: Treeline is valued at $2.5B, Standard BioTools at $460M, and Treeline holders will own 84% of the combined company. Standard BioTools stockholders receive CVRs tied to legacy asset sales. A shareholder vote and reverse split are required to close.

check_boxKey Events · M&A and Partnerships · LAB

• Reverse Merger Terms Finalized

  Treeline Biosciences is valued at $2.5B, while Standard BioTools is valued at $460M on a net-cash-adjusted basis. Treeline stockholders will receive approximately 11.6997 Standard BioTools shares for each Treeline share, resulting in 84% ownership of the combined company.

• CVR Dividend for Standard BioTools Holders

  Each Standard BioTools stockholder will receive one contingent value right (CVR) per share, entitling them to proceeds from the sale of legacy businesses, convertible notes, milestone payments, and any surplus net cash, capped at 76M shares over 5 years.

• Shareholder Vote and Reverse Split Required

  The merger requires approval of the share issuance under Nasdaq Rule 5635 and a reverse stock split—with a ratio range to be set—to meet Nasdaq's $4.00 minimum bid price for the combined company's listing under the ticker 'TRLN'.

• Combined Company Cash Runway into 2029

  Pro forma cash and equivalents of approximately $1.06B are expected at close, which management estimates will fund Treeline's oncology pipeline—including TLN-121, TLN-254, TLN-372, and TLN-499—into 2029.

auto_awesomeAnalysis · LAB · Industrial Applications And Services

The S-4 registration statement filed by Standard BioTools lays out the full terms of its all-stock reverse merger with Treeline Biosciences, a clinical-stage oncology company. For the first time, investors can see the deal's specifics: Treeline is valued at $2.5 billion, while Standard BioTools is valued at $460 million on a net-cash-adjusted basis, giving Treeline stockholders 84% of the combined entity. As part of the transaction, each Standard BioTools share will carry one contingent value right (CVR), providing holders with proceeds from the sale of the company's legacy businesses and other assets. This merger marks a transformative pivot from life sciences tools to a biotech centered on Treeline's pipeline of targeted protein degraders and small molecules. Closing the deal hinges on shareholder approval of the share issuance and a reverse stock split to meet Nasdaq listing requirements. The S-4 also includes fairness opinions, detailed risk factors, and pro forma financials that project over $1 billion in cash for the combined company, sufficient to fund operations into 2029. This filing represents a critical step toward completing the merger, which is expected in the second half of 2026.